1 |
Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res. 2001;7(5):1410-8.
|
2 |
Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the pathway. J Biol Chem. 1999;274(38):27307-14.
DOI
|
3 |
Herrmann C, Block C, Geisen C, Haas K, Weber C, Winde G, et al. Sulindac sulfide inhibits Ras signaling. Oncogene. 1998;17(14):1769-76.
DOI
|
4 |
Waddell WR, Miesfeld RL. Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac. J Surg Oncol. 1995;58(4):252-6.
DOI
|
5 |
Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, et al. Apoptosis primarily accounts for the growthinhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxy-genase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997;57(12):2452-9.
|
6 |
Park MK, Kim MK, Kim JC, Sung YK. Pattern of apoptosis by NS398, a selective COX-2 inhibitor, in hepatocellular carcinoma cell lines. Cancer Res Treat. 2005;37(5):313-7.
DOI
|
7 |
Cheng AS, Chan HL, Leung WK, Wong N, Johnson PJ, Sung JJ. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Oncol. 2003;23(1):113-9.
|
8 |
Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer research. 1987;47(18):4967-72.
|
9 |
Schiff ER, Maddrey WC, Sorrell MF. Schiff's diseases of the liver. Philadelphia: Lippincott-Raven Publishers; 1999. p. 1281-304.
|
10 |
Kew MC. Hepatic tumors and cysts. Sleisenger & Fordtran's gastrointestinal and liver disease: pathology/diagnosis/management. Philadelphia: Saunders; 1998. p. 1365-87.
|
11 |
Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;350(9085):1142-3.
|
12 |
Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet. 1998;351(9097):214-5.
|
13 |
El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33(1):62-5.
DOI
|
14 |
Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37(5):431-502.
DOI
|
15 |
Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med. 2002;139(4):234-43.
DOI
|
16 |
Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest. 1997;100(6):1325-9.
DOI
|
17 |
Buttar NS, Wang KK, editors. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors. Mayo Clin Proc. 2000;75(10):1027-38.
DOI
|
18 |
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8(3):289-93.
DOI
|
19 |
Cheng J, Imanishi H, Iijima H, Shimomura S, Yamamoto T, Amuro Y, et al. Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res. 2002;23(3):185-95.
DOI
|
20 |
Weddle DL, Tithoff P, Williams M, Schuller HM. -adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis. 2001;22(3):473-9.
DOI
|
21 |
Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002;13(5):669-78.
DOI
|
22 |
Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000;30(2):73-81.
DOI
|
23 |
Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294(5548):1871-5.
DOI
|
24 |
Seno H, Oshima M, Ishikawa T-o, Oshima H, Takaku K, Chiba T, et al. Cyclooxygenase 2-and prostaglandin receptor -dependent angiogenesis in mouse intestinal polyps. Cancer research. 2002;62(2):506-11.
|
25 |
Richter M, Weiss M, Weinberger I, Fürstenberger G, Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis. 2001;22(1):17-25.
DOI
|
26 |
Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol. 2003;9(6):1302-6.
DOI
|
27 |
Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122(5):518-23.
|
28 |
Harizi H, Gualde N. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens. 2005;65(6):507-14.
DOI
|
29 |
Karin M. Nuclear factor- in cancer development and progression. Nature. 2006;441(7092):431-6.
DOI
|
30 |
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
DOI
|
31 |
Cheng J, Imanishi H, Amuro Y, Hada T. Ns-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer. 2002;99(5):755-61.
DOI
|
32 |
Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther. 1990;254(1):180-7.
|
33 |
Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clinical cancer research. 2005;11(22):8213-21.
DOI
|
34 |
Heiduschka G, Erovic BM, Vormittag L, Skoda C, Martinek H, Brunner M, et al. -hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2009;135(3):261-7.
DOI
|
35 |
Park W, Oh YT, Han JH, Pyo H. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2. J Exp Clin Cancer Res. 2008;27(1):66.
DOI
|
36 |
Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97(11):1523-31.
DOI
|
37 |
Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol. 1993;45(8):753-5.
DOI
|
38 |
Mejza F, Nizankowska E. [Selective inhibitors of cyclooxygenase-2 (COX-2)]. Postepy Hig Med Dosw. 2001;55(2):287-302. Polish.
|
39 |
Zarghi A, Sabakhi I, Topuzyan V, Hajimahdi Z, Daraie B. Design, synthesis and biological evaluation of 5-oxo-1, 4, 5, 6, 7, 8 hexahydroquinoline derivatives as selective cyclooxygenase-2 inhibitors. Iran J Pharm Res. 2014;13:61-9.
DOI
|
40 |
Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908-16.
DOI
|
41 |
Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 1999;29(3):688-96.
DOI
|
42 |
Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H, Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res. 2000;60(8):2085-9.
|
43 |
Hu KQ, Yu CH, Mineyama Y, McCracken JD, Hillebrand DJ, Hasan M. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Int J Oncol. 2003;22(4):757-63.
|